Smith+Nephew (LON:SN) is touting what it is describing as outstanding clinical results for its total hip arthroplasty (THA) portfolio.
The results — in both the National Joint Registry for England, Wales and Northern Ireland (NJR) and the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) — involve Smith+Nephew’s POLAR3 total hip offering. The POLAR3 combines S+N’s Polarstem cementless stem, R3 acetabular system and Oxinium technology.
The NJR 2020 annual report, according to Smith+Nephew, showed that the Polarstem and R3 combo had the highest implant survivorship (98.46%) of all cementless hip constructs at 10 years, with 72% lower revision risk over the same period.
On top of that, the recently issued AOANJRR 2020 annual report found that Smith+Nephew’s proprietary Oxinium technology, which involves ceramicised metal on XLPE, continued to have the lowest revision rate of all hip bearing combinations at 15 years, the company said.
“There are now four prominent registries with mid- to long-term data confirming that our Oxinium technology has the highest survivorship,” said Vasant Padmanabhan, president of global R&D for Smith+Nephew. “With these milestone results, orthopedic surgeons can be more confident than ever in recommending POLAR3 as best performing cementless hip construct and bearing combination on the market today to their patients.”
